Company

Cytokinetics, Incorporated

Headquarters: South San Francisco, CA, United States

Founded: 1997

Employees: 253

CEO: Mr. Robert I. Blum

NASDAQ: CYTK -8.19%

Market Cap

$6.50 Billion

USD as of July 1, 2024

Market Cap History

Cytokinetics, Incorporated market capitalization over time

Evolution of Cytokinetics, Incorporated market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Cytokinetics, Incorporated

Detailed Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Cytokinetics, Incorporated has the following listings and related stock indices.


Stock: NASDAQ: CYTK wb_incandescent

Stock: FSX: KK3A wb_incandescent

Product & Services

Omecamtiv mecarbilReldesemtivCK-3773274

Key People

Founder(s): James Spudich Ronald Vale James Sabry Lawrence S. B. Goldstein

Robert Blum (President & CEO) Fady Malik (Executive VP) Ching Jaw (CFO) Stuart Kupfer (CMO) Robert Califf (Board of Directors)

Financials

Revenue: $ 56 Million(2020)

Details

Headquarters:

280 East Grand Avenue

South San Francisco, CA 94080

United States

Phone: 650 624 3000

Fax: 650 624 3070